Keywords: اتازناویر; Atazanavir; Myocardial infarction; High mobility group box-1 protein; Toll-like receptor 9;
مقالات ISI اتازناویر (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: اتازناویر; Overweight; Body composition; Antiretroviral drugs; Drug monitoring; Efavirenz; Atazanavir; Darunavir;
Keywords: اتازناویر; Population pharmacokinetics; NONMEM; Atazanavir; Dose optimisation; Thai patients; HIV-infected patients;
Keywords: اتازناویر; Atazanavir; Raltegravir; HIV; NRTI-sparing antiretroviral therapy; Treatment-experienced patients;
Keywords: اتازناویر; in vitro/in vivo correlations (IVIVC); hepatic transport; hepatic metabolism; hepatic clearance; hepatocytes; HIV/AIDS; membrane transport; metabolism; organic anion-transporting polypeptide transporters; APV; amprenavir; ATV; atazanavir; CHO; Chinese h
Keywords: اتازناویر; 3TC; Lamivudine; ABC; Abacavir; ARV; Antiretroviral; ATV; Atazanavir; AZT; Zidovudine; d4T; Stavudine; DRV; Darunavir; EFV; Efavirenz; FTC; Emtricitabine; L&D; Labor and delivery; LOQ; Limit of quantification; LPV; Lopinavir; M8; NFV hydroxy-tert-butylami
HIV aspartyl protease inhibitors modify the percentage of activated leukocytes, as well as serum levels of IL-17A and NO during experimental leishmaniasis
Keywords: اتازناویر; Leishmania; Lopinavir; Atazanavir; Lymphocytes; Nitric Oxide; Cytokines;
Determination of genotoxic impurity in atazanavir sulphate drug substance by LC-MS
Keywords: اتازناویر; GTI; Atazanavir; LC-MS; ICH; QL; DL;
Lipophilic salts of poorly soluble compounds to enable high-dose lipidic SEDDS formulations in drug discovery
Keywords: اتازناویر; 2-NSA; 2-naphthalene sulfonic acid; ATV; atazanavir; ATF-2-NSA; atazanavir-2-naphthalene sulfonic acid; ATV-Doc; atazanavir-dioctyl sulfosuccinic acid; Doc; dioctyl sulfosuccinic acid; Lipophilic salt; Atazanavir; 2-naphthalene sulfonic acid; Dioctyl sulf
Cardiovascular risk in advanced naïve HIV-infected patients starting antiretroviral therapy: Comparison of three different regimens - PREVALEAT II cohort
Keywords: اتازناویر; HIV; Cardiovascular risk; Atherosclerosis; Darunavir; Atazanavir; Efavirenz;
Effects of antiretroviral treatment on paraoxonase 1 (PON1) activity in rats
Keywords: اتازناویر; Paraoxonase; Antiretroviral therapy; Protease inhibitors; Dyslipidemia; Atherosclerosis; ART; Active Antiretroviral Therapy; ATV; atazanavir; HAART; Highly Active Antiretroviral Therapy; Hcy; homocysteine; HDL; High-density lipoprotein; HIV; Human Immunod
Factors involved in continuance of atazanavir-based regimens: Results from a cohort of HIV1-positive patients
Keywords: اتازناویر; Atazanavir; Unboosted; Continuance; Antiretroviral; HIV;
Nephrotoxicity induced by drugs: The case of foscarnet and atazanavir-A SEM and μFTIR investigation
Keywords: اتازناویر; Infrared microscopy; Kidney biopsy; Crystal deposits; Drug-induced renal failure; Foscarnet; Atazanavir;
LMNA mutations resulting in lipodystrophy and HIV protease inhibitors trigger vascular smooth muscle cell senescence and calcification: Role of ZMPSTE24 downregulation
Keywords: اتازناویر; Vascular smooth muscle cells; ZMPSTE24; Prelamin A; Senescence; Osteogenic transdifferentiation; Atherosclerosis; ALP; alkaline phosphatase; ATV; atazanavir; DRV; darunavir; HIV; human immunodeficiency virus; LPV; lopinavir; M/R; maraviroc/raltegravir; PB
Heme oxygenase-1-derived bilirubin counteracts HIV protease inhibitor-mediated endothelial cell dysfunction
Keywords: اتازناویر; PI; protease inhibitors; ROS; reactive oxygen species; HO-1; heme oxygenase-1; CO; carbon monoxide; CORM2; carbon monoxide releasing molecule-2; iCORM2; inactivated carbon monoxide releasing molecule-2; CM-H2DCFDA; 5-(and-6)-chloromethyl-2,7-dichlorodihyd
Assessment of long-term safety and effectiveness of atazanavir (ATV) in the first antiretroviral treatment regimen in POLCA cohort
Keywords: اتازناویر; HIV; cART; Atazanavir; Late presenters; Safety; Effectiveness
Metabolic abnormalities and cardiovascular risk in HIV-infected cohort of patients treated with protease inhibitors
Keywords: اتازناویر; cART; Cardiovascular risk in HIV patients; Lipid parameters; Atazanavir; Lopinavir
Herb-drug interaction between an anti-HIV Chinese herbal SH formula and atazanavir in vitro and in vivo
Keywords: اتازناویر; SH formula; Atazanavir; Anti-HIV; CYP3A2; Herb-drug interaction;
Prediction of pH dependent absorption using in vitro, in silico, and in vivo rat models: Early liability assessment during lead optimization
Keywords: اتازناویر; pH dependent solubility; Gastric pH; GastroPlusâ¢; Rat pH dependent absorption model; Ketoconazole; Atazanavir; Exposure;
Anti-HIV drugs, lopinavir/ritonavir and atazanavir, modulate innate immune response triggered by Leishmania in macrophages: The role of NF-κB and PPAR-γ
Keywords: اتازناویر; Lopinavir/ritonavir; Atazanavir; Leishmania; Cytokines; PPAR-γ; RelB/NFκB;
Coadministration of tenofovir decreased atazanavir plasma concentration after unilateral nephrectomy
Keywords: اتازناویر; Atazanavir; Tenofovir; Human immunodeficiency virus type 1; Therapeutic drug monitoring; Drug interaction; Nephrectomy;
Comparative analysis of ER stress response into HIV protease inhibitors: Lopinavir but not darunavir induces potent ER stress response via ROS/JNK pathway
Keywords: اتازناویر; APV; Amprenavir; ARE; antioxidant response; ATV; Atazanavir; cART; Combination antiretroviral therapy; DRV; Darunavir; FDA; Food and Drug Administration; IDV; Indinavir; LDH; lactate dehydrogenase; LPV; Lopinavir; NAC; N-acetyl-L-cysteine; NFV; Nelfinavir
Keywords: اتازناویر; adverse effects; antiretroviral therapy; atazanavir; darunavir; health care costs; Medicaid
Related factors to atazanavir plasma levels in a cohort of HIV positive individuals with undetectable viral load
Keywords: اتازناویر; Atazanavir; Plasma levels; Drug concentration; Ritonavir; Lipid profile
High frequency of antiviral drug resistance and non-B subtypes in HIV-1 patients failing antiviral therapy in Cuba
Keywords: اتازناویر; ART; antiretroviral therapy; CI; confidence interval; NRTI; nucleoside reverse transcriptase inhibitor; NNRTI; non-nucleoside RTI; PI; protease inhibitor; FCR; full-class resistance; CRF; circulating recombinant form; HIV; human immunodeficiency virus; MD
Comparison of extraction procedures for assessment of matrix effect for selective and reliable determination of atazanavir in human plasma by LC–ESI-MS/MS
Keywords: اتازناویر; Atazanavir; Indinavir; Post-column infusion; Ion-suppression; Extraction procedures; LC–ESI-MS/MS; Human plasma
Atazanavir in pregnancy: impact on neonatal hyperbilirubinemia
Keywords: اتازناویر; HIV; Pregnancy; Atazanavir; Placental transfer; Neonatal hyperbilirubinemia
Outcomes of switch to atazanavir-containing combination antiretroviral therapy in HIV-1-infected patients with hyperlipidemia
Keywords: اتازناویر; Atazanavir; Combination antiretroviral therapy; HIV infection; Hyperlipidemia
Influence of atazanavir on the pharmacodynamics and pharmacokinetics of gliclazide in animal models
Keywords: اتازناویر; Gliclazide; Atazanavir; Diabetes; HIV infection; Hypoglycemia; Pharmacokinetics
Effect of serum lipids on the pharmacokinetics of atazanavir in hyperlipidemic rats
Keywords: اتازناویر; HIV; Atazanavir; Pharmacokinetics; Hyperlipidemia
The HIV-1 protease resistance mutation I50L is associated with resistance to atazanavir and susceptibility to other protease inhibitors in multiple mutational contexts
Keywords: اتازناویر; PI, protease inhibitor; RWF, resistance weight factor; FC, fold change; CCO, clinical cut-off; ARV, anti-retroviral; HAART, highly active anti-retroviral therapyI50L; Atazanavir; PI hyper-susceptibility; Predicted phenotypic resistance; Clinically relevan
Association between serum bilirubin levels and ABCB1 3435 variant in HIV-1 infected, atazanavir treated individuals
Keywords: اتازناویر; atazanavir; pharmacogenetics; ABCB1 polimorphisms
Evolution of the HIV-1 protease region in heavily pretreated HIV-1 infected patients receiving Atazanavir
Keywords: اتازناویر; HIV-1; Atazanavir; Drug resistance; Viral evolution; Phylogenesis;
Quantification of protease inhibitors and non-nucleoside reverse transcriptase inhibitors in dried blood spots by liquid chromatography–triple quadrupole mass spectrometry
Keywords: اتازناویر; Antiretroviral; HIV; Therapeutic drug monitoring; TDM; LC–MS; Chromatography; Mass spectrometry; Dried blood spots; Dried blood spot; Bioanalysis; Pharmacokinetics; Protease inhibitors; Non-nucleoside reverse transcriptase inhibitors; Atazanavir; Darunavi
A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations
Keywords: اتازناویر; HIV-1; Drugs; Second line; Synthesis; Prices; Efavirenz; Tenofovir Disoproxil Fumarate; TDF; Emtricitabine; FTC; Ritonavir; Lopinavir; Kaletra; Atazanavir
Interaction between buprenorphine and atazanavir or atazanavir/ritonavir
Keywords: اتازناویر; Buprenorphine/naloxone; Atazanavir; Ritonavir; Drug interactions
Gene expression profiling of rat liver reveals a mechanistic basis for ritonavir-induced hyperlipidemia
Keywords: اتازناویر; Ritonavir; Atazanavir; Proteasome; Hyperlipidemia
Simple determination of the HIV protease inhibitor atazanavir in human plasma by high-performance liquid chromatography with UV detection
Keywords: اتازناویر; Atazanavir; BMS-232632; HIV protease inhibitors; Solid-phase extraction; High-performance liquid chromatography; Therapeutic drug monitoring
Determination of atazanavir in human plasma using solid-phase extraction and high-performance liquid chromatography
Keywords: اتازناویر; Reversed-phase chromatography; Solid-phase extraction; Protease inhibitors; Atazanavir; Therapeutic drug monitoring;
Effets indésirables induits par les traitements antirétroviraux
Keywords: اتازناویر; ABC; abacavir; APV; amprénavir; ARV; antiretroviral; ASAT; aspartate aminotransférase; ATZ; atazanavir; AZT; zidovudine; ddI; didanosine; d4T; stavudine; EFV; éfavirenz; EI; effet indésirable; FTC; emtricitabine; HDL; lipoprotéine de haute densité;
Intracellular measurements of anti-HIV drugs indinavir, amprenavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, efavirenz and nevirapine in peripheral blood mononuclear cells by liquid chromatography coupled to tandem mass spectrometry
Keywords: اتازناویر; Protease inhibitors; Non-nucleoside reverse transcriptase inhibitors; PBMCs; Peripheral blood mononuclear cells; HPLC-MS/MS; Indinavir; Amprenavir; Saquinavir; Ritonavir; Nelfinavir; Lopinavir; Atazanavir; Efavirenz; Nevirapine;